The Long Run with Luke Timmerman
"The Long Run"
Antarctic explorer Ernest Shackleton would appreciate today's biotech. Scientific entrepreneurs of the 21st century must be ready for what Shackleton called the “hazardous journey, bitter cold, long months of complete darkness, constant danger, safe return doubtful, honor and recognition in case of success.” Today, the men and women who strive to apply science for the betterment of human health have a historic opportunity. They need stamina and resilience to achieve something meaningful. Biotech’s relationship with the society that sustains it has never been more tenuous.
Join host Luke Timmerman for in-depth, thought-provoking conversations with biotech newsmakers pursuing these great opportunities of the 21st century.
Latest episodes
Dec 13, 2023 • 1h 4min
Ep150: Jeff Jonker on the Small Molecule Drug Discovery Renaissance
Jeff Jonker, CEO of Belharra Therapeutics, discusses the renaissance in small molecule drug discovery. Topics include their accidental entry into biotech, the significance of building relationships in the industry, the appeal of sustainable platform companies, chemo proteomics, small molecule binders and covalent bonds in drug discovery, and covalent and non-covalent binding in small molecule drug discovery.
7 snips
Nov 29, 2023 • 1h 2min
Ep149: Nancy Stagliano on Precision Neuroscience
Nancy Stagliano, CEO of Neuron23, discusses precision medicine in neuroscience drug discovery. Topics include genetic underpinnings of Parkinson's, studying neurodegeneration, transitioning from academia to biotech, challenges in drug discovery, focusing on Alzheimer's lead program, genetic links to neurological disorders, and future of targeted treatments.
Nov 13, 2023 • 1h 3min
Ep148: Diana Brainard on the Fight Against Infectious Disease
Diana Brainard, CEO of AlloVir, on leading the fight against infectious diseases.
Nov 1, 2023 • 1h 9min
Ep147: Reid Huber on Investing in the Future of Medicine
Reid Huber, partner at Third Rock Ventures, discusses investing in the future of medicine. The podcast covers his journey from genetics to drug discovery, reflections on a long-term career, transitioning into venture capitalism, navigating the stock market and legislation impact, and revolutionizing medical oncology through clinical trials and innovation.
Oct 17, 2023 • 1h 47min
Ep146: Jeff Huber on Life in Tech and Biotech
Jeff Huber, co-founder and general partner at Triatomic Capital, shares his career journey from tech to biotech. He discusses early cancer detection, using computers to enhance business processes, approaches to cancer treatment, and the development of a new cancer screening method. The chapter also examines the acquisition of Grail by Illumina and the regulatory challenges. Jeff also shares his inspiring adventure in Everest Base Camp and highlights the progress and impact in the biotech industry.
Oct 3, 2023 • 1h 7min
Ep145: Lori Lyons-Williams on Targeted Radiopharmaceuticals for Cancer
Lori Lyons-Williams, CEO of Abdera Therapeutics, on developing targeted radiopharmaceuticals for cancer.
Sep 19, 2023 • 1h 5min
Ep144: Turning the Tables, Rob Perez Interviews Me
Turning the Tables, Rob Perez Interviews Me
Sep 6, 2023 • 1h 10min
Ep143: Zach Weinberg and Alexis Borisy on Freeing the Biotech Founders
Explore the journey of Curie.Bio founders Zach Weinberg and Alexis Borisy in empowering biotech entrepreneurs. Learn about the hands-on support offered to founders, the evolution of Flatiron Health, and the collaborative approach of Curie Bio in prioritizing founder ownership and control in the biotech industry.
Aug 24, 2023 • 56min
Ep142: Fred Appelbaum on how 'Living Medicine' Came to Be
Fred Appelbaum, a physician, scientist and leader at the Fred Hutchinson Cancer Center, on 'Living Medicine,' his new book about the development of bone marrow transplantation and the rise of cell therapy.
Aug 8, 2023 • 1h 10min
Ep141: Colin Hill on Digging Deep into Data, Finding New Drug Targets
Colin Hill, co-founder and CEO of Aitia, on digging deep into biological datasets and finding new drug targets.
